Novartis bets up to $7.8B for an mRNA-encoded T cell engager from China’s Abogen

Summary

Novartis has licensed an mRNA-based T cell engager therapy from China's Abogen Biosciences in a deal valued at up to $7.8 billion. The in vivo therapy is designed to produce a CD3xCD19 T cell engager inside the body, potentially reducing dangerous cytokine release.